ValiRx plc, a biotechnology oncology focused company, engages in developing novel treatments for cancer and associated biomarkers in the United Kingdom. Its proprietary GeneICE technology enables the selective silencing of specific genes by targeted histone deacetylation leading to chromatin condensation. The company's lead drug candidates include VAL201, an anti-cancer therapeutic that is in Phase I/II trials for the treatment of prostate cancer and other indications of hormone induced unregulated growth, including endometriosis; VAL301, a reformulation of VAL201, which is in pre-clinical development for the non-invasive and better tolerated treatment of endometriosis; and VAL401, a reformulation of generic drug Risperidone, which has completed Phase II clinical trials for the treatment of non-small cell lung cancer.
Read More…
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone+44-20-30084416
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees12
Next Earnings DateN/A
OptionableNot Optionable
ValiRx (LON:VAL) Frequently Asked Questions
What is ValiRx's stock symbol?
ValiRx trades on the London Stock Exchange (LON) under the ticker symbol "VAL."
How were ValiRx's earnings last quarter?
ValiRx Plc (LON:VAL) issued its earnings results on Tuesday, April, 10th. The company reported ($1.90) earnings per share for the quarter, topping the Zacks' consensus estimate of ($2.60) by $0.70. View ValiRx's Earnings History.
Has ValiRx been receiving favorable news coverage?
Press coverage about VAL stock has been trending somewhat positive this week, InfoTrie reports. The research group ranks the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. ValiRx earned a media sentiment score of 1.8 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the next few days. View News Stories for ValiRx.
Who are some of ValiRx's key competitors?
Some companies that are related to ValiRx include Race Oncology (RAC), Ovoca Bio (OVB), e-Therapeutics (ETX), Factor Therapeutics (FTT), Galena Biopharma (SLS), SalvaRx Group (SALV), Can-Fite Biopharma (CANF), CAN-FITE BIOPHA/S (CANF), Nanollose (NC6), Medifocus (MFS), IBEX Technologies (IBT), Novacyt (NCYT), BPH Energy (BPH), Innovotech (IOT) and Cotinga Pharmaceuticals (COT).
What other stocks do shareholders of ValiRx own?
Who are ValiRx's key executives?
ValiRx's management team includes the folowing people:
- Dr. Satu Vainikka, Founding Director & CEO (Age 52)
- Mr. James Gerry Desler, Founding Director & CFO (Age 63)
- Dr. George Morris, Founding Director & COO (Age 63)
- Mr. Kevin Alexander, Sec. & Non-Exec. Director (Age 63)
- Mr. Tarquin Edwards, Head of Investor Relations & Communications
How do I buy shares of ValiRx?
Shares of VAL and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is ValiRx's stock price today?
One share of VAL stock can currently be purchased for approximately GBX 0.23.
How big of a company is ValiRx?
What is ValiRx's official website?
How can I contact ValiRx?
ValiRx's mailing address is 3rd Fl, 16 Upper Woburn Place, LONDON, WC1H 0BS, United Kingdom. The company can be reached via phone at +44-20-30084416.
MarketBeat Community Rating for ValiRx (LON VAL)
MarketBeat's community ratings are surveys of what our community members think about ValiRx and other stocks. Vote "Outperform" if you believe VAL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VAL will underperform the S&P 500 over the long term. You may vote once every thirty days.
